38.14 -0.90 (-2.31%)
Pre-Market: 7:20AM EST
Previous Close | 42.01 |
Open | 41.41 |
Bid | 0.00 x 1100 |
Ask | 37.68 x 900 |
Day's Range | 37.71 - 41.85 |
52 Week Range | 7.41 - 61.59 |
Volume | 5,297,128 |
Avg. Volume | 4,521,050 |
Market Cap | 7.677B |
Beta (5Y Monthly) | 2.03 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.47 |
Earnings Date | Feb 17, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 54.60 |
The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.
What happened Shares of Invitae (NYSE: NVTA) had fallen 6.6% as of 3:13 p.m. EST on Wednesday. The medical genetics company didn't announce any news that would cause the stock to drop. Instead, Invitae's decline today appears to be part of a broader sell-off of high-growth stocks, with the Nasdaq Composite Index falling 2%.
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, in collaboration with Invitae Corporation (NYSE: NVTA, "Invitae"), a leading medical genetics company, announces the launch of a sponsored genetic testing program, navigateAPDS, designed to assist clinicians in identifying patients and their family members with activated PI3K delta syndrome (APDS), which may lead to earlier diagnosis.